Citable filing context
MRK's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Merck reported Q2 2026 worldwide sales of $16.6 billion and a GAAP loss per share of $0.54. |
| May 28, 2026 | other | Merck & Co. shareholders voted on directors, executive compensation, and other proposals at the Annual Meeting. |
| May 22, 2026 | debt_offering | MRK closed a $6 billion public offering of floating and fixed-rate notes. |
| Aug 4, 2026 | Guidance: non_gaap_eps | 2.66 to 2.76 |
| Aug 4, 2026 | Guidance: revenue | 66300.00 to 67300.00 |
| Apr 30, 2026 | Guidance: non_gaap_effective_income_tax_rate | 23.50 to 24.50 |
| Aug 7, 2026 | mda_quarterly | Merck & Co. reported worldwide sales of $16.6 billion for the second quarter of 2026, a 5% increase year-over-year, driven by strong performance in oncology and cardiometabolic franchises. Keytruda/Keytruda Qlex remains the primary growth engine, with combined global sales rising 5% in the quarter. The cardiometabolic segment saw significant momentum from the uptake of Winrevair and the inclusion of Ohtuvayre. Conversely, the company faced headwinds in diabetes, with Januvia and Janumet sales declining 31% due to competitive pressure and the loss of U.S. market exclusivity in May 2026. Infectious disease revenue also fell, largely due to lower demand for Lagevrio and generic competition for Dificid. Financial results were heavily impacted by aggressive business development. Merck recorded $14.7 billion in research and development charges during the first half of 2026, primarily driven by the $9.0 billion acquisition of Cidara Therapeutics and the $6.8 billion acquisition of Terns Pharmaceuticals. These asset acquisitions, alongside ongoing restructuring programs aimed at optimizing the manufacturing network, resulted in a net loss for the period. The company continues to navigate significant pricing pressures, including U.S. government price-setting under the Inflation Reduction Act and international cost-containment measures, which remain key risks to long-term profitability. |
| May 4, 2026 | mda_quarterly | Merck reported a significant net loss of $(4,240) million for the first quarter ended March 31, 2026, a substantial decline from the $5,079 million net income in the prior year period. This downturn was primarily driven by a massive increase in Research and Development expenses, which surged to $12,592 million from $3,621 million year-over-year. Sales increased modestly to $16,286 million from $15,529 million. Other contributing factors to the loss included higher Cost of Sales, Selling, General and Administrative expenses, and Restructuring Costs, alongside a shift in Other (income) expense, net from a $35 million income to a $138 million expense. Basic earnings per share swung to a loss of $(1.72) from a profit of $2.01. Concurrently, the company repurchased 7,659,590 shares of common stock at an average price of $114.07 during the quarter, as part of a $10 billion share repurchase program approved in January 2025. Approximately $6,447 million remained available under this authorization as of quarter-end. No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors or executive officers. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
MRK company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.